Gilead’s Covid-19 Drug is Mediocre. It Will Be a Blockbuster Anyway.

Gilead Sciences said Wednesday that remdesivir, which has been authorized for emergency use since the spring, brought in $873 million in revenues so far this year.
By BY KATIE THOMAS from NYT Health https://ift.tt/34BnUum
via IFTTT
your-feed-science, Coronavirus (2019-nCoV), Drugs (Pharmaceuticals), Remdesivir (Drug), Research, Company Reports
Source New York Times
Làm đẹp Blog 247